Influenza Treatments in the Pipeline
Edina Avdic, PharmD, MBA, BCPS-AQ ID, discusses 2 investigational influenza treatments for pharmacists to keep an eye on. This video was filmed at the ASHP (American Society of Health-System Pharmacists) 54th Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada.
Edina Avdic, PharmD, MBA, BCPS-AQ ID: So, there are 2 other agents that are currently investigational for the treatment of influenza. Those are pimodivir, which is a polymerase complex inhibitor. [It is] similar to baloxavir, which inhibits the viral cell replication. That agent, however, is only active against influenza A, not against influenza B, and is being investigated both as an IV and PO formulation.
The other agent also works on the polymerase complex, again, similar area as baloxavir, which inhibits viral cell replication. And that agent is also being investigated as an IV and PO formulation, and it’s active against both influenza A and B. It is currently FDA-approved in Japan for use in avian influenza that is resistant to oseltamivir.